3Theodore W, Kurtz, Michal Prawenec. Antidiabetic mechanisrm of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the rennin-angiotensin system [J]. Journal of Hypertension, 2004, 22(12): 2253-2261.
4Savage DB,Tan GD, AceriniCL,et al. Human metabolic syndrome resulting from domainant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-γ[J]. Diabetes, 2003, 52: 910-917.
5Pershadsingh HA. Peroxisome proliferator-activated receptor-γ: therapeutic target for diseases beyond diabetes: Quo vadis[J]? Expert Opin Invest Drugs,2004,13:215 - 228.
6Berger J, Moller DE. The mechanisms of action of PPARs [ J ]. Annu Rev Med, 2002, 53 : 409 - 435.
7A. W. Krug, M. Ehrhart-Bornstein. Newly disenvered endocrine functions of white adipose tissue: possible relevance in obesity-related diseasea[J]. Journal Cellular and Molecular Life Sciences (CMLS),2005,62:1359- 1362.
8Sharma A. M, Chetty V. T. Obesity, hypertension and insulin resistance [ J ]. Acta Diabetologica, 2005,42 Suppl: S3 - 8.
9Kamal Rahmouni, Marcelo L.G. Correia, William G. Haynes, et al. Obesity-Associated Hypertension New Insights Into Mechanisms[J]. Hypertension, 2005,45:9- 14.
